After regulatory delays and manufacturing issues caused Bristol Myers Squibb investors to miss out on the lucrative Celgene contingent value right, the closely watched CAR-T drug liso-cel has finally scored an FDA nod.  On Friday, the…

After AstraZeneca’s Imfinzi in late 2018 failed a trial in head and neck cancer, the company pinned its hopes on the phase 3 Kestrel study, figuring the drug might be…

With supply contracts for 50 million COVID-19 vaccine doses in Japan and 40 million in South Korea, Moderna has already made a push into the Asian market. Now, it’s laying out plans…

Regeneron’s bullish outlook for its COVID-19 antibody therapy continues to outpace its sales figures, but strong Dupixent and Eylea revenues in the fourth quarter eased some of its immediate pressure…

Early in the COVID-19 pandemic, as researchers scrambled to find medicines that could treat the new and mysterious disease, Gilead Sciences’ remdesivir quickly marched to worldwide prominence based on promising…